Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
FR0012333284
Fri, 30.09.2022
ABIVAX
ABIVAX ANNOUNCES THE RELEASE OF ITS 2022 HALF-YEAR FINANCIAL REPORT
PARIS, France, September 30, 2022 – 06:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a phase 3 clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, [ … ]
Fri, 30.09.2022
ABIVAX
ABIVAX ANNOUNCES THE RELEASE OF ITS 2022 HALF-YEAR FINANCIAL REPORT
PARIS, France, September 30, 2022 – 06:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a phase 3 clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, [ … ]
Tue, 27.09.2022
ABIVAX
Abivax abstract on obefazimod phase 2b results selected for moderated poster presentation at UEG Week 2022
Obefazimod (ABX464) interim 48-week safety and efficacy analysis from the ongoing phase 2b maintenance study in moderate-to-severe ulcerative colitis (UC) selected by UEG as “one of the best abstracts” and eligible for an oral presentation at [ … ]
Tue, 27.09.2022
ABIVAX
Abivax abstract on obefazimod phase 2b results selected for moderated poster presentation at UEG Week 2022
Obefazimod (ABX464) interim 48-week safety and efficacy analysis from the ongoing phase 2b maintenance study in moderate-to-severe ulcerative colitis (UC) selected by UEG as “one of the best abstracts” and eligible for an oral presentation at [ … ]
Thu, 15.09.2022
ABIVAX
ABIVAX PRESENTS FIRST-HALF 2022 FINANCIAL RESULTS AND OPERATIONS UPDATE
Obefazimod global pivotal phase 3 clinical program in ulcerative colitis on track with US IRB approval granted and first-patient-in expected end of September 2022
Excellent results from the obefazimod phase 2b open-label maintenance study in moderate to severe ulcerative coli [ … ]
Thu, 15.09.2022
ABIVAX
ABIVAX PRESENTS FIRST-HALF 2022 FINANCIAL RESULTS AND OPERATIONS UPDATE
Obefazimod global pivotal phase 3 clinical program in ulcerative colitis on track with US IRB approval granted and first-patient-in expected end of September 2022
Excellent results from the obefazimod phase 2b open-label maintenance study in moderate to severe ulcerative coli [ … ]
Tue, 06.09.2022
ABIVAX
ABIVAX PHASE 2B STUDY RESULTS OF OBEFAZIMOD (ABX464) IN ULCERATIVE COLITIS PUBLISHED IN THE LANCET GASTROENTEROLOGY & HEPATOLOGY
Phase 2b induction trial and 48-week extension results of obefazimod in ulcerative colitis (UC) published in the prestigious, peer-reviewed journal “The Lancet Gastroenterology & Hepatology”
Scientific community [ … ]
Tue, 06.09.2022
ABIVAX
ABIVAX PHASE 2B STUDY RESULTS OF OBEFAZIMOD (ABX464) IN ULCERATIVE COLITIS PUBLISHED IN THE LANCET GASTROENTEROLOGY & HEPATOLOGY
Phase 2b induction trial and 48-week extension results of obefazimod in ulcerative colitis (UC) published in the prestigious, peer-reviewed journal “The Lancet Gastroenterology & Hepatology”
Scientific community [ … ]
Fri, 02.09.2022
ABIVAX
ABIVAX PUBLISHES A PROSPECTUS IN THE CONTEXT OF ITS CAPITAL INCREASE
PARIS, FRANCE, September 2, 2022 – 20.30 p.m. (CEST) – Abivax (Euronext Paris: FR0012333284 – ABVX) (the “Company”), a phase 3 clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, toda [ … ]
Fri, 02.09.2022
ABIVAX
ABIVAX PUBLISHES A PROSPECTUS IN THE CONTEXT OF ITS CAPITAL INCREASE
PARIS, FRANCE, September 2, 2022 – 20.30 p.m. (CEST) – Abivax (Euronext Paris: FR0012333284 – ABVX) (the “Company”), a phase 3 clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, toda [ … ]